Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olostar FDC Adherence Study in Hypertension and Dyslipidemia
NCT04061824Phase 4Completed
- Sponsor
- Yonsei University
- Start
- May 2016
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of olmesartan and rosuvastatin in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Yonsei University. Primary endpoint: Compliance of prescribed medication at 26 weeks. Started May 2016; status: completed.
02
Drugs
olmesartanrosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04061824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061824.